# US 2021/0079367 A1 · Novel crispr-associated (cas) protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079367 A1
- Document ID: US20210079367A1
- Status: Published application
- Kind: A1
- Application number: 17/097,880
- Filed: 2020-11-13
- Published: 2021-03-18
- Earliest claimed: 2017-03-28
- Assignees: Locanabio, Inc.
- Applicants: Locanabio, Inc.
- Inventors: Matthew Merrill Carter; Paul Daniel Donohoue
- Web page: https://patentgrep.com/patent/US20210079367A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- C12N 15/85: for animal cells
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- Y02A 40/146: Genetically Modified [GMO] plants, e.g. transgenic plants
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.

## Claims

### Claim 1

A Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) nucleoprotein complex, wherein the nucleoprotein complex comprises a Cas protein having at least 95 percent sequence identity to the amino acid sequence of SEQ ID NO: 40; and
a cognate nucleic acid guide comprising a repeat sequence and a spacer sequence, wherein the repeat sequence and the spacer sequence do not naturally occur together, wherein the Cas protein and the cognate nucleic acid guide form the nucleoprotein complex, and wherein the nucleoprotein complex is capable of site-directed binding to a target nucleic acid sequence.

### Claim 2 (depends on 1)

The Cas nucleoprotein complex of claim 1, wherein the cognate nucleic acid guide comprises a crRNA.

### Claim 3 (depends on 1)

The Cas nucleoprotein complex of claim 1, wherein the Cas protein comprises an N- or C-terminal nuclear localization signal sequence (NLS).

### Claim 4 (depends on 1)

The Cas nucleoprotein complex of claim 1, wherein the cognate nucleic acid guide comprises a modified base analog.

### Claim 5 (depends on 1)

The Cas nucleoprotein complex of claim 1, wherein the sequence identity is calculated using BLAST computer program with default parameters.

### Claim 6 (depends on 1)

A eukaryotic cell comprising the Cas nucleoprotein complex of claim 1.

### Claim 7 (depends on 6)

The eukaryotic cell of claim 6, further comprising one or more additional Cas nucleoprotein complexes.

### Claim 8 (depends on 7)

The eukaryotic cell of claim 7, wherein the eukaryotic cell is a human cell.

### Claim 9 (depends on 1)

The Cas nucleoprotein complex of claim 1, wherein the Cas protein is catalytically active.

### Claim 10 (depends on 1)

The Cas nucleoprotein complex of claim 1, wherein the Cas protein is catalytically inactive.

### Claim 11 (depends on 1)

The Cas nucleoprotein complex of claim 1, wherein the Cas protein comprises a fusion protein.

### Claim 12

An expression cassette comprising:
a polynucleotide encoding:
a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) protein, wherein the Cas protein has at least 95 percent sequence identity to the amino acid sequence of SEQ ID NO: 40; and
one or more cognate nucleic acid guides, wherein the one or more cognate nucleic acid guides comprise a repeat sequence and a spacer sequence, wherein the repeat sequence and the spacer sequence do not naturally occur together, wherein the Cas protein is capable of forming one or more nucleoprotein complexes with the one or more cognate nucleic acid guides, and wherein each nucleoprotein complex is capable of site-directed binding to a target nucleic acid sequence.

### Claim 13 (depends on 12)

The expression cassette of claim 12, wherein the Cas protein is catalytically active.

### Claim 14 (depends on 12)

The expression cassette of claim 12, wherein the Cas protein is catalytically inactive.

### Claim 15 (depends on 12)

The expression cassette of claim 12, further comprising one or more nucleic acid sequences each encoding a nuclear localization tag operably linked to the polynucleotide encoding the Cas protein.

### Claim 16 (depends on 12)

A recombinant vector, comprising the expression cassette of claim 12.

### Claim 17 (depends on 12)

A eukaryotic cell, comprising the expression cassette of claim 12.

### Claim 18 (depends on 16)

The recombinant vector of claim 16, wherein the vector is a viral vector.

### Claim 19

A method of directing a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) nucleoprotein complex to a selected nucleic acid target sequence, the method comprising:
contacting the selected nucleic acid target sequence with one or more nucleoprotein complexes comprising:
a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) protein, wherein the Cas protein has at least 95 percent sequence identity to the amino acid sequence of SEQ ID NO: 40; and
a cognate nucleic acid guide comprising a repeat sequence and a spacer sequence, wherein the repeat sequence and the spacer sequence do not naturally occur together, wherein the Cas protein and the cognate nucleic acid guide form the nucleoprotein complex, and wherein the nucleoprotein complex binds to the selected nucleic acid target sequence.

### Claim 20 (depends on 19)

The method of claim 19, wherein the nucleic acid target sequence comprises RNA.

### Claim 21 (depends on 19)

The method of claim 19, wherein the method is performed in a cell.

### Claim 22 (depends on 19)

The method of claim 19, wherein the nucleoprotein complex is capable of site-directed binding to the nucleic acid target sequence.
